Testing Effect Homogeneity and Confounding in High-Dimensional Experimental and Observational Studies

Economists Ana Armendariz and Martin Huber have published a groundbreaking methodological paper introducing a new framework for testing the homogeneity of Conditional Average Treatment Effects (CATEs) across multiple studies. Their approach, detailed in arXiv:2602.19703, tackles a fundamental problem in evidence synthesis: determining whether treatment effects observed in randomized controlled trials (RCTs) remain consistent when applied to real-world observational data or different experimental settings. The core innovation lies in using multiple RCTs as a benchmark; if CATEs are homogeneous across them, it suggests the absence of problematic interactions between the treatment and unobserved variables. This framework is then extended to compare RCT results with observational data, where deviations can signal unobserved confounding, effect heterogeneity, or both.

The methodology leverages double machine learning to handle high-dimensional covariates in a data-driven way, making it suitable for modern datasets with many variables. The researchers demonstrated its application on the International Stroke Trial (IST), a large multi-country RCT involving over 20,000 patients testing aspirin's effect on acute ischemic stroke outcomes. Their test provides a flexible tool for validating the key identification assumptions behind popular methods like instrumental variables and difference-in-differences. For professionals, this means a more rigorous way to assess whether a 'local' effect estimated for a specific subpopulation (e.g., 'compliers' in an IV study) can be safely extrapolated to the total population, directly impacting how we generalize findings from clinical trials and econometric studies to inform policy and practice.